Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979492810> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2979492810 abstract "Abstract Abstract 4929 In a previous multi-center Phase II study, lenalidomide resulted in a 43% overall hematologic response with 26% of patients achieving transfusion independence (TI) among 214 non-del(5q) red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System (IPSS) lower-risk MDS (Raza et al Blood. 2008). A single institution follow-up trial was conducted in patients with low or Int-1 risk non-del(5q) MDS, a platelet count of >50, 000 and requiredat least 2 units of blood required in 8 weeks. Fifty-six patients received lenalidomide at a starting dose of 10 mg qday. There were 41 males and 15 females, and the median age was 71 years. By IPSS, 27 had low-risk disease and 22 had Int-1-risk disease, while IPSS could not be assigned for 7 patients. By cytogenetics, 38 patients had a normal karyotype, 12 showed abnormalities, while data could not be obtained for 4 patients due to culture failure. Morphologic classification consisted of: RA=17, RCMD=16, RARS=4, RCMD-RS=7, RARS-T=1 and RAEB-1=11. Median duration of MDS was 12 months (range 1–120 months). Median transfusion requirement was 2 units in 8 weeks prior to starting therapy. Median duration of lenalidomide therapy was 4 months (range, 1–36+ months). Treatment was generally well tolerated. The most common Grade 3/4 toxicity was myelosuppression, with 17 (30%) experiencing thrombocytopenia, 12/(21%) neutropenia and 1 leukopenia (2%). Other Grade 3/4 toxicities included diarrhea (7%) rash (2%), and fatigue (2%). At least one dose reduction was required for 33 (59%) patients. Intent-to-treat analysis showed hematologic response (HI) by the IWG-R criteria in 23 (41%) patients, no response in 25(44%) patients, and other failure in 8 (14%) patients. Among the 23 responders, 18 (32%) achieved TI. Median time to response was 2 cycles (6 weeks), with 6 patients responding in cycle 1, 9 in cycle 2, 5 in cycle 3 and 1 each in cycles 4, 5, 6, respectively. Median duration of response was 294 days (approximately 10 months), with durations ranging from 44+ days to 936+ days (+ indicates continuing response). We confirm in this 56-patient, single institution phase II study that lenalidomide has substantial clinical activity in transfusion-dependent, lower-risk non-del(5q) MDS, with results comparable to those previously reported in the multi-center phase II study. Disclosures: No relevant conflicts of interest to declare." @default.
- W2979492810 created "2019-10-18" @default.
- W2979492810 creator A5022414149 @default.
- W2979492810 creator A5024299617 @default.
- W2979492810 creator A5071920263 @default.
- W2979492810 creator A5072840140 @default.
- W2979492810 creator A5075616701 @default.
- W2979492810 creator A5087963156 @default.
- W2979492810 date "2012-11-16" @default.
- W2979492810 modified "2023-10-02" @default.
- W2979492810 title "Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Patients with Low and Intermediate-1 Risklower-Risk, Non-Del(5q) Myelodysplastic Syndromes (MDS))): Results From a Single-Institution Phase II Study" @default.
- W2979492810 doi "https://doi.org/10.1182/blood.v120.21.4929.4929" @default.
- W2979492810 hasPublicationYear "2012" @default.
- W2979492810 type Work @default.
- W2979492810 sameAs 2979492810 @default.
- W2979492810 citedByCount "0" @default.
- W2979492810 crossrefType "journal-article" @default.
- W2979492810 hasAuthorship W2979492810A5022414149 @default.
- W2979492810 hasAuthorship W2979492810A5024299617 @default.
- W2979492810 hasAuthorship W2979492810A5071920263 @default.
- W2979492810 hasAuthorship W2979492810A5072840140 @default.
- W2979492810 hasAuthorship W2979492810A5075616701 @default.
- W2979492810 hasAuthorship W2979492810A5087963156 @default.
- W2979492810 hasConcept C126322002 @default.
- W2979492810 hasConcept C141071460 @default.
- W2979492810 hasConcept C2776063141 @default.
- W2979492810 hasConcept C2776364478 @default.
- W2979492810 hasConcept C2776694085 @default.
- W2979492810 hasConcept C2777063308 @default.
- W2979492810 hasConcept C2778248108 @default.
- W2979492810 hasConcept C2778570526 @default.
- W2979492810 hasConcept C2780007613 @default.
- W2979492810 hasConcept C2780014101 @default.
- W2979492810 hasConcept C2780240888 @default.
- W2979492810 hasConcept C2780817109 @default.
- W2979492810 hasConcept C2780873365 @default.
- W2979492810 hasConcept C71924100 @default.
- W2979492810 hasConcept C90924648 @default.
- W2979492810 hasConceptScore W2979492810C126322002 @default.
- W2979492810 hasConceptScore W2979492810C141071460 @default.
- W2979492810 hasConceptScore W2979492810C2776063141 @default.
- W2979492810 hasConceptScore W2979492810C2776364478 @default.
- W2979492810 hasConceptScore W2979492810C2776694085 @default.
- W2979492810 hasConceptScore W2979492810C2777063308 @default.
- W2979492810 hasConceptScore W2979492810C2778248108 @default.
- W2979492810 hasConceptScore W2979492810C2778570526 @default.
- W2979492810 hasConceptScore W2979492810C2780007613 @default.
- W2979492810 hasConceptScore W2979492810C2780014101 @default.
- W2979492810 hasConceptScore W2979492810C2780240888 @default.
- W2979492810 hasConceptScore W2979492810C2780817109 @default.
- W2979492810 hasConceptScore W2979492810C2780873365 @default.
- W2979492810 hasConceptScore W2979492810C71924100 @default.
- W2979492810 hasConceptScore W2979492810C90924648 @default.
- W2979492810 hasLocation W29794928101 @default.
- W2979492810 hasOpenAccess W2979492810 @default.
- W2979492810 hasPrimaryLocation W29794928101 @default.
- W2979492810 hasRelatedWork W2093483613 @default.
- W2979492810 hasRelatedWork W2280923005 @default.
- W2979492810 hasRelatedWork W2463213105 @default.
- W2979492810 hasRelatedWork W2510411798 @default.
- W2979492810 hasRelatedWork W2530606198 @default.
- W2979492810 hasRelatedWork W2550855140 @default.
- W2979492810 hasRelatedWork W2551241036 @default.
- W2979492810 hasRelatedWork W2553696906 @default.
- W2979492810 hasRelatedWork W2557851135 @default.
- W2979492810 hasRelatedWork W2578097465 @default.
- W2979492810 hasRelatedWork W2586377746 @default.
- W2979492810 hasRelatedWork W2590746929 @default.
- W2979492810 hasRelatedWork W2593942699 @default.
- W2979492810 hasRelatedWork W2907930551 @default.
- W2979492810 hasRelatedWork W2978434317 @default.
- W2979492810 hasRelatedWork W2979424133 @default.
- W2979492810 hasRelatedWork W2979952576 @default.
- W2979492810 hasRelatedWork W2980007933 @default.
- W2979492810 hasRelatedWork W2980857653 @default.
- W2979492810 hasRelatedWork W2994050739 @default.
- W2979492810 isParatext "false" @default.
- W2979492810 isRetracted "false" @default.
- W2979492810 magId "2979492810" @default.
- W2979492810 workType "article" @default.